41 results on '"COSMI B"'
Search Results
2. OC 46.1 Absolute Quantitative Proteomics for Occult Cancer Screening in Patient with Unprovoked Venous Thromboembolism: Results from the Prospective PLATO-VTE Study
3. PB0479 The ABC-Bleeding Score for Prediction of On-Treatment Clinically Relevant Bleeding in Patients with Unprovoked Venous Thromboembolism: Results from the Prospective PLATO-VTE Study
4. Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants
5. External validation of the DASH prediction rule: a retrospective cohort study
6. Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH
7. Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment
8. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
9. Current management strategies and long‐term clinical outcomes of upper extremity venous thrombosis
10. OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism
11. Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis
12. Management of superficial vein thrombosis
13. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: reply
14. D‐dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut‐off values for an assay with results expressed in D‐dimer units
15. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
16. The Wells rule and D‐dimer for the diagnosis of isolated distal deep vein thrombosis
17. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)
18. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
19. Sex, age and normal post‐anticoagulation D‐dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension
20. PO-33 D-dimer testing to determine duration of anticoagulation and risk of occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study
21. Residual Venous Obstruction, alone and in Combination with D-Dimer, as a Risk Factor for Recurrence after Anticoagulation Withdrawal following a First Idiopathic Deep Vein Thrombosis in the Prolong Study
22. D-dimer and Factor VIII are Independent Risk Factors for Recurrence After Anticoagulation Withdrawal for a First Idiopathic Deep Vein Thrombosis
23. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism
24. THE COURSE OF D-DIMER AND FACTOR VIII LEVELS DURING THE ACUTE PHASE OF LEG DEEP VENOUS THROMBOSIS AND RELATIONSHIP WITH THE THROMBOTIC BURDEN
25. D-DIMER TESTING AND RECURRENT VENOUS THROMBOEMBOLISM AFTER UNPROVOKED PULMONARY EMBOLISM
26. PO-24 Elevated levels of Factor VIII in patients with multiple myeloma treated with thalidomide
27. D-dimer testing to determine the duration of anticoagulation therapy
28. Value of D‐dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes
29. Risk factors for highly unstable response to oral anticoagulation: response to Murphy
30. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence
31. d‐Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal
32. Is There a Role for Oral Anticoagulant Therapy in Patients with Peripheral Arterial Disease?
33. Atherothrombosis and the pill: what ratio(nale) for the RATIO studies?
34. Venous thromboembolism, oral contraceptives and high prothrombin levels
35. Thrombophilia in young women candidate to the pill: reasons for and against screening
36. Family history and risk of venous thromboembolism with oral contraception
37. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study
38. The additive effect of dermatan sulfate and low molecular weight heparins on thrombin inhibition in vitro
39. The relationship between antithrombin III levels and the anticoagulant effect of standard heparin
40. Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits
41. Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.